PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trial
Official title:
MRI Imaging to Predict Outcomes of Treatment in PDAC Patients
The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).
The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e. vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT06122896 -
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
|
Early Phase 1 | |
Recruiting |
NCT05262855 -
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05947825 -
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
|
Phase 2 | |
Recruiting |
NCT06151223 -
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
|
||
Recruiting |
NCT05845801 -
Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
|
||
Recruiting |
NCT05853198 -
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
|
N/A | |
Recruiting |
NCT05669287 -
Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics
|
N/A | |
Recruiting |
NCT05727020 -
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
|
||
Recruiting |
NCT05218889 -
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05132244 -
Monitoring and Managing Glucose Levels in People With Pancreatic Cancer
|
N/A | |
Recruiting |
NCT04365049 -
Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma
|